Bausch+Lomb Results Presentation Deck
YTD Total Bausch+Lomb P&L¹ (Non-GAAP)²
Bausch + Lomb
Vision Care Revenue 4
Surgical Revenue
Pharmaceuticals Revenue 4
Total Revenue
Adj. Gross Profit²
Adj. Gross Margin²
R&D
R&D % of Revenues
Adj. SG&A²
Adj. SG&A % of Revenues³
Adj. EBITA²
Depreciation
Stock Based Compensation
Adj. EBITDA 2,3
Adj. EBITDA Margin²
Adj. Net Income Attributable to Bausch + Lomb²
Adj EPS Attributable to Bausch + Lomb2,4
BAUSCH + LOMB
1Q23-2Q23
$1,233M
$378M
$355M
$1,966M
$1,177M
59.9%
$162M
8.2%
$789M
40.1%
$226M
$71M
$42M
$320M
16.3%
$99M
$0.28
1Q22-2Q225
$1,148M
$358M
$324M
$1,830M
$1,103M
60.3%
$152M
8.3%
$700M
38.3%
$251M
$64M
$27M
$352M
19.2%
$188M
$0.54
Reported Change
7%
6%
10%
7%
7%
(40 bps)
(7%)
(13%)
(10%)
11%
56%
(9%)
(47%)
Constant Currency Change²
10%
8%
12%
10%
9%
(7%)
(15%)
(6%)
11%
56%
(5%)
(40%)
1. Products with sales outside the United States impacted by F/X changes.
2. This is a non-GAAP measure or ratio. See Slide 1 and Appendix for further information on non-GAAP measures and ratios.
3. Includes transactional FX and NCI. Currency headwind (translational and transactional) was -$40M to Adj. EBITDA for YTD2023. The YTD2022 transactional FX impact was a gain of $15M.
4. Effective in the first quarter of 2023, certain products historically included in the reported results of the Pharmaceuticals segment are now included in the reported results of the Vision Care segment and certain products included in the reported results of
the Vision Care segment are now included in the reported results of the Pharmaceuticals segment. Management believes these movements are necessary in order to better align these products with the groupings of similar products. The net impact of
these product movements was not material to the periods presented. Prior period presentations of segment revenues have been conformed to the current segment reporting structure.
5. YTD 2022 results were not fully burdened by all stand-up costs associated with the separation.
28View entire presentation